226260-01-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-N-methoxy-N-methylbenzamide is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique chemical structure, including the fluorine atom and amide group, allows it to be a key component in the development of new drugs, potentially enhancing their stability, reactivity, and interaction with biological targets.
Used in Materials Development:
3-Fluoro-N-methoxy-N-methylbenzamide is used as a building block in the creation of new materials with specific properties. 3-FLUORO-N-METHOXY-N-METHYLBENZAMIDE's ability to form strong bonds with other elements and participate in hydrogen bonding makes it a valuable component in the design of materials with tailored characteristics for various applications, such as in electronics or coatings.

InChI:InChI=1/C9H10FNO2/c1-11(13-2)9(12)7-4-3-5-8(10)6-7/h3-6H,1-2H3

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 1711-07-5 3-fluorobenzoyl chloride 
• 455-38-9 3-fluorobenzoic acid 
• 1892-57-5 N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 926931-57-9 1-(3-fluorophenyl)-3-(methoxymethylamino)propan-1-one 
• 1628416-28-3 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide 
• 107-02-8 acrolein 
• 170301-01-6 6-fluoro-2-phenyl-4H-benzo<2,3-d>-1,3-oxazin-4-one 
• 345-71-1 (3-fluorophenyl)(4-fluorophenyl)methanone 
• 42916-68-7 1-(3-fluorophenyl)-pentan-1-one 
• 345-70-0 3,3'-difluorobenzophenone 

Relevant academic research and scientific papers

HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT

The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and can thus be usefully used in the treatment of lung cancer.

Fluoro-Substituted Methyllithium Chemistry: External Quenching Method Using Flow Microreactors

The external quenching method based on flow microreactors allows the generation and use of short-lived fluoro-substituted methyllithium reagents, such as fluoromethyllithium, fluoroiodomethyllithium, and fluoroiodostannylmethyllithium. Highly chemoselective reactions have been developed, opening new opportunities in the synthesis of fluorinated molecules using fluorinated organometallics.

AZA-PYRIDONE COMPOUNDS AND USES THEREOF

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compound. Examples of an orthomyxovirus viral infection include an influenza infection.

AZA-PYRIDONE COMPOUNDS AND USES THEREOF

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount o

Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors

A small library of 36 functionalized benzophenone thiosemicarbazone analogs has been prepared by chemical synthesis and evaluated for their ability to inhibit the cysteine proteases cathepsin L and cathepsin B. Inhibitors of cathepsins L and B have the potential to limit or arrest cancer metastasis. The six most active inhibitors of cathepsin L (IC50 50 > 10,000 nM). The most active analog in the series, 3-bromophenyl-2′-fluorophenyl thiosemicarbazone 1, also efficiently inhibits cell invasion of the DU-145 human prostate cancer cell line.

1-Acyldihydropyrazole Derivatives

Compounds of the formula (I), in which R1, R2, R3a, R3b, R3c and R3d have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

TUBULIN INHIBITORS

Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).

PYRAZINE-BASED TUBULIN INHIBITORS

A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating a hyperproliferation-related disease state or disorder in a subject using a compound of formula (I) is also described

Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)

The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases.